- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 235/14 - Radicals substituted by nitrogen atoms
Patent holdings for IPC class C07D 235/14
Total number of patents in this class: 292
10-year publication summary
|
17
|
17
|
18
|
18
|
23
|
19
|
15
|
15
|
16
|
8
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Abbvie Inc. | 1802 |
6 |
| Actelion Pharmaceuticals Ltd | 533 |
6 |
| LG Chem, Ltd. | 17561 |
5 |
| The General Hospital Corporation | 4704 |
5 |
| X4 Pharmaceuticals, Inc. | 77 |
5 |
| VALO Health, Inc. | 172 |
5 |
| Centre National de La Recherche Scientifique | 10321 |
4 |
| Sumitomo Chemical Company, Limited | 9009 |
4 |
| Kyoto University | 2793 |
4 |
| Nippon Shinyaku Co., Ltd. | 329 |
4 |
| Cavion, Inc. | 21 |
4 |
| Calico Life Sciences LLC | 96 |
4 |
| AstraZeneca AB | 2928 |
3 |
| Janssen Pharmaceutica N.V. | 3423 |
3 |
| Allergan, Inc. | 2362 |
3 |
| The Board of Trustees of the University of Illinois | 2683 |
3 |
| Takeda Pharmaceutical Company Limited | 2704 |
3 |
| Antabio SAS | 22 |
3 |
| Concert Pharmaceuticals, Inc. | 251 |
3 |
| Epizyme, Inc. | 370 |
3 |
| Other owners | 212 |